Skip to Main Content

Nektar Therapeutics said Monday that its experimental immunotherapy failed to provide additional benefit for patients with melanoma when given in combination with Bristol Myers Squibb’s approved treatment Opdivo.

The negative trial results cast significant doubt on the future of Nektar’s lead pipeline drug called bempegaldesleukin, which is designed to stimulate T cells in the body of cancer patients, thereby enhancing the tumor-killing power of other immunotherapy treatments.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment